The invention comprises the use of LGF in the production of medicinal products that can be used in the pleiotropic tissue regeneration of one or more damaged tissues, in which at least one of the damaged tissues forms part of the central nervous system and the medicinal product is intended to be administered systemically. The invention is based on the fact that intraperitoneal administration of LGF can promote a positive effect on a Parkinsons disease model. As such, in a preferred embodiment of the invention, the medicinal product is intended for the treatment of Parkinsons disease, particularly when the medicinal product is intended for humans.
